Advertisement

Central European Journal of Medicine

, Volume 5, Issue 2, pp 261–267 | Cite as

Association of osteoprotegerin and rankl levels with insulin resistance in pubertal obese children

  • Ediz Yeşilkaya
  • Aysun Bideci
  • Orhun Çamurdan
  • Mehmet Boyraz
  • Sebahattin Vurucu
  • Peyami Cinaz
Article
  • 55 Downloads

Abstract

Osteoprotegerin (OPG)/“receptor activator of nuclear factor kappa B-ligand” (RANKL) system has an important role in the remodeling of bone through regulation of osteoclastogenesis. We aimed to detect OPG and RANKL levels, particularly in obese children in the pubertal period and to investigate whether these parameters correlate with insulin resistance in childhood. Our study included 66 obese children ranging in age from 9.1 to 16 years, and 22 non-obese children ranging in age from 10.5 to 16 years. Blood glucose, insulin, total cholesterol, HDL cholesterol, and LDL cholesterol levels were measured for all cases; HOMA-IR, Quicki index and atherogenic index were calculated. Serum OPG and RANKL levels were also measured. OPG and RANKL levels did not show any difference between obese and non-obese children (P>.05). No difference in these 2 parameters were observed among the children with and without insulin resistance (P>.05). No correlation could be established between the OPG, the HOMA-IR, Quick and atherogenic indices. Obesity and insulin resistance are believed to show their effect in the later period of life to become able to change some of the parameters.

Keywords

Henoch-Schönlein purpura Nephrotic syndrome Adulthood 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Alemzadeh R., Rising R., Lifshitz F., Obesity in Children, In: Lifshitz F., Editor. Pediatric Endocrinology. New York: Healthcare, 2007, 1–36Google Scholar
  2. [2]
    Güngör N., Arslanian S.A., Nutritional disorders, In: Sperling M.A., Editor. Pediatric Endocrinology. Philadelphia: Saunders, 2002, 689–724Google Scholar
  3. [3]
    Hasanoğlu A., Bideci A., Cinaz P., Tümer L., Unal S, Bone mineral density in childhood obesity., J. Pediatr. Endocrinol. Metab., 2000, 13, 307–311PubMedGoogle Scholar
  4. [4]
    Rocher E., Chappard C., Jaffre C., Benhamou CL., Courteix D., Bone mineral density in prepubertal obese and control children: relation to body weight, lean mass, and fat mass., J. Bone. Miner. Metab., 2008, 26, 73–78CrossRefPubMedGoogle Scholar
  5. [5]
    Schoppet M., Preissner K.T., Hofbauer L.C., RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function., Arterioscler. Thromb. Vasc. Biol., 2002, 22, 549–553CrossRefPubMedGoogle Scholar
  6. [6]
    Browner W.S., Lui L.Y., Cummings S.R., Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women., J. Clin. Endocrinol. Metab., 2001, 86, 631–637CrossRefPubMedGoogle Scholar
  7. [7]
    Indridason O.S., Franzson L., Sigurdsson G., Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover., Osteoporos. Int., 2005, 16, 417–423CrossRefPubMedGoogle Scholar
  8. [8]
    Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification., Genes. Dev., 1998, 12, 1260–1268CrossRefPubMedGoogle Scholar
  9. [9]
    Rogers A., Saleh G., Hannon R.A., Greenfield D., Eastell R., Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women., J. Clin. Endocrinol. Metab., 2002, 87, 4470–4475CrossRefPubMedGoogle Scholar
  10. [10]
    Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 2007; 56: 977–983CrossRefPubMedGoogle Scholar
  11. [11]
    Franck H., Meurer T., Hofbauer L.C., Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis., J. Rheumatol., 2004, 31, 2236–2241PubMedGoogle Scholar
  12. [12]
    Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al., Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis., J. Exp. Med., 2000, 192, 463–474CrossRefPubMedGoogle Scholar
  13. [13]
    Anand D.V., Lahiri A., Lim E., Hopkins D., Corder R., The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects., J. Am. Coll. Cardiol., 2006, 47, 1850–1857CrossRefPubMedGoogle Scholar
  14. [14]
    Bundak R., Furman A., Gunoz H., Darendeliler F., Bas F., Neyzi O., Body mass index references for Turkish children., Acta. Paediatr., 2006, 95, 194–198CrossRefPubMedGoogle Scholar
  15. [15]
    Keskin M., Kurtoglu S., Kendirci M., Atabek M.E., Yazici C., Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents., Pediatrics, 2005, 115, e500–503CrossRefPubMedGoogle Scholar
  16. [16]
    Buzi F., Maccarinelli G., Guaragni B., Ruggeri F., Radetti G., Meini A., et al., Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome and rheumatoid arthritis., Clin. Endocrinol. (Oxf)., 2004, 60, 87–91CrossRefGoogle Scholar
  17. [17]
    Misra M., Soyka L.A., Miller K.K., Herzog D.B., Grinspoon S., De Chen D., et al., Serum osteoprotegerin in adolescent girls with anorexia nervosa., J. Clin. Endocrinol. Metab., 2003, 88, 3816–3822CrossRefPubMedGoogle Scholar
  18. [18]
    Ugur-Altun B., Altun A., Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women., Arch. Med. Res., 2007, 38, 891–896CrossRefPubMedGoogle Scholar
  19. [19]
    Oh E.S., Rhee E.J., Oh K.W., Lee W.Y., Baek K.H., Yoon K.H., et al., Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women., Metabolism, 2005, 54, 49–54CrossRefPubMedGoogle Scholar
  20. [20]
    Gannagé-Yared M.H., Yaghi C., Habre B., Khalife S., Noun R., Germanos-Haddad M., et al., Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study., Eur. J. Endocrinol., 2008, 158, 353–359CrossRefPubMedGoogle Scholar
  21. [21]
    Szulc P., Hofbauer L.C., Heufelder A.E., Roth S., Delmas P.D., Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status., J. Clin. Endocrinol. Metab., 2001, 86, 3162–3165CrossRefPubMedGoogle Scholar
  22. [22]
    Swolin-Eide D., Magnusson P., Hansson S., Bone mass, biochemical markers and growth in children with chronic kidney disease: a 1-year prospective study., Acta Paediatr., 2007, 96, 720–725CrossRefPubMedGoogle Scholar
  23. [23]
    Angelopoulos N.G., Goula A., Katounda E., Rombopoulos G., Kaltzidou V., Kaltsas D., et al., Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with betathalassemia major., J. Bone. Miner. Metab., 2007, 25, 60–67CrossRefPubMedGoogle Scholar
  24. [24]
    Ugur-Altun B., Altun A., Gerenli M., Tugrul A., The relationship between insulin resistances assessed by HOMA-IR and serum osteoprotegerin levels in obesity., Diabetes Res. Clin. Pract., 2005, 68, 217–222CrossRefPubMedGoogle Scholar
  25. [25]
    Gannagé-Yared M.H., Fares F., Semaan M., Khalife S., Jambart S., Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population., Clin. Endocrinol. (Oxf)., 2006, 64, 652–658CrossRefGoogle Scholar
  26. [26]
    Altun A., Ugur-Altun B., Tatli E., Decreased serum osteoprotegerin levels in patients with cardiac syndrome X., J. Endocrinol. Invest., 2004, 27, 839–843PubMedGoogle Scholar
  27. [27]
    Kim S.M., Lee J., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., et al., Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity., Clin. Endocrinol. (Oxf)., 2005, 63, 594–598CrossRefGoogle Scholar
  28. [28]
    Uemura H., Yasui T., Miyatani Y., Yamada M., Hiyoshi M., Arisawa K., et al., Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women., Menopause, 2008, 15, 180–184PubMedGoogle Scholar
  29. [29]
    Dovio A., Allasino B., Palmas E., Ventura M., Pia A., Saba L., et al., Increased osteoprotegerin levels in Cushing’s syndrome are associated with an adverse cardiovascular risk profile., J. Clin. Endocrinol. Metab., 2007, 92, 1803–1808CrossRefPubMedGoogle Scholar
  30. [30]
    Rhee E.J., Oh K.W., Jung C.H., Lee W.Y., Oh E.S., Yun E.J., et al., The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans., Clin. Endocrinol. (Oxf)., 2006, 64, 689–697CrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Ediz Yeşilkaya
    • 1
  • Aysun Bideci
    • 1
  • Orhun Çamurdan
    • 1
  • Mehmet Boyraz
    • 1
  • Sebahattin Vurucu
    • 2
  • Peyami Cinaz
    • 1
  1. 1.Department of Pediatric EndocrinologyGazi University Medical SchoolAnkaraTurkey
  2. 2.Department of Pediatric NeurologyGülhane Military Medical AcademyAnkaraTurkey

Personalised recommendations